Stockreport

J&J and Protagonist's icotrokinra scores in Phase IIb UC study [Yahoo! Finance]

Protagonist Therapeutics, Inc.  (PTGX) 
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.protagonist-inc.com
PDF IIb study in patients with moderately to severely active ulcerative colitis (UC). J&J conducted the ANTHEM-UC trial (NCT06049017) of icotrokinra, an investigational ta [Read more]